Form 8-K - Current report:
SEC Accession No. 0001193125-25-027245
Filing Date
2025-02-14
Accepted
2025-02-14 16:01:22
Documents
14
Period of Report
2025-02-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d890894d8k.htm   iXBRL 8-K 29327
2 EX-3.1 d890894dex31.htm EX-3.1 35406
  Complete submission text file 0001193125-25-027245.txt   206011

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aard-20250214.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aard-20250214_lab.xml EX-101.LAB 19483
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aard-20250214_pre.xml EX-101.PRE 12172
16 EXTRACTED XBRL INSTANCE DOCUMENT d890894d8k_htm.xml XML 3991
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Filer) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42513 | Film No.: 25628062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)